CETP and hyperlipidemia: This network meta‐analysis included 33 randomized controlled trials (RCTs) with 120,292 participants evaluating cholesteryl ester transfer protein (CETP) inhibitors (anacetrapib, evacetrapib, dalcetrapib, obicetrapib, torcetrapib) versus placebo, statins, or other lipid‐lowering therapies in adults with hyperlipidemia.